62,066 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Virtu Financial LLC

Virtu Financial LLC purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 62,066 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Virtu Financial LLC owned about 0.08% of Ocular Therapeutix as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of OCUL. Barclays PLC boosted its stake in shares of Ocular Therapeutix by 22.9% during the 3rd quarter. Barclays PLC now owns 25,963 shares of the biopharmaceutical company’s stock valued at $81,000 after buying an additional 4,840 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Ocular Therapeutix by 142.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,756 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 5,730 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Ocular Therapeutix by 350.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,192 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 7,152 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Ocular Therapeutix by 60.5% in the 4th quarter. SG Americas Securities LLC now owns 19,646 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 7,404 shares during the last quarter. Finally, Raymond James & Associates raised its stake in shares of Ocular Therapeutix by 7.0% in the 4th quarter. Raymond James & Associates now owns 129,012 shares of the biopharmaceutical company’s stock valued at $575,000 after purchasing an additional 8,451 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on OCUL shares. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Ocular Therapeutix in a research note on Friday, June 14th. Piper Sandler reiterated an “overweight” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Friday, June 14th. StockNews.com lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. JMP Securities reduced their price objective on Ocular Therapeutix from $24.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 8th. Finally, TD Cowen raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and increased their target price for the stock from $7.00 to $11.00 in a report on Thursday. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Ocular Therapeutix Price Performance

Shares of OCUL opened at $6.08 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 21.39 and a quick ratio of 21.29. The company has a market cap of $941.73 million, a P/E ratio of -4.50 and a beta of 1.42. Ocular Therapeutix, Inc. has a 12 month low of $2.00 and a 12 month high of $11.31. The stock has a fifty day moving average price of $5.71 and a 200 day moving average price of $6.23.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $14.77 million for the quarter, compared to the consensus estimate of $15.43 million. Ocular Therapeutix had a negative return on equity of 76.64% and a negative net margin of 192.61%. On average, research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.